Lantern Pharma Announces Peer-Reviewed Publication of Phase 1a LP-184 Data in Recurrent Glioblastoma, Supporting a Phase 1b/2a Combination Trial with Spironolactone
Lantern Pharma's Stralight Therapeutics Publishes LP-184 Phase 1a GBM Data, Establishing The Recommended Dose For Expansion And A Clinically Translatable Dosing Strategy For The Planned Phase 1b/2a Trial
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026
Lantern Pharma secures Taiwan clearances for Phase II NSCLC study
Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC
Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering
Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering
Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development - Slideshow
Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development Transcript
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
Lantern Pharma Issued Notice Of Allowance From U.S. Patent And Trademark Office For Application Titled Method For Treating Blood Cancers
Lantern Pharma Q2 2026 Earnings Call: Complete Transcript
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI-Driven Pipeline Advances Amid ...
Lantern Pharma Inc. 2026 Q2 - Results - Earnings Call Presentation
Lantern Pharma Inc. Q2 2026 Earnings Call Summary
Lantern Pharma Inc. (LTRN) Q2 2026 Earnings Call Transcript
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.